Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):778-786. doi: 10.1002/psp4.12247. Epub 2017 Sep 28.
Being able to scale preclinical pharmacodynamic response to clinical would be beneficial in drug development. In this work, the integrated glucose insulin (IGI) model, developed on clinical intravenous glucose tolerance test (IVGTT) data, describing dynamic glucose and insulin concentrations during glucose tolerance tests, was scaled to describe data from similar tests performed in healthy rats, mice, dogs, pigs, and humans. Several approaches to scaling the dynamic glucose and insulin were investigated. The theoretical allometric exponents of 0.75 and 1, for clearances and volumes, respectively, could describe the data well with some species-specific adaptations: dogs and pigs showed slower first phase insulin secretion than expected from the scaling, pigs also showed more rapid insulin dependent glucose elimination, and rodents showed differences in glucose effectiveness. The resulting scaled IGI model was shown to accurately predict external preclinical IVGTT data and may be useful in facilitating translations of preclinical research into the clinic.
能够将临床前药效反应进行缩放,对于药物开发将是有益的。在这项工作中,基于临床静脉葡萄糖耐量试验 (IVGTT) 数据开发的综合葡萄糖胰岛素 (IGI) 模型,描述了葡萄糖耐量试验期间动态葡萄糖和胰岛素浓度,将其缩放以描述在健康大鼠、小鼠、狗、猪和人中进行的类似试验的数据。研究了几种缩放动态葡萄糖和胰岛素的方法。清除率和体积的理论体表面积指数分别为 0.75 和 1,可以很好地描述数据,但需要一些物种特异性的调整:狗和猪的第一相胰岛素分泌比预期的缩放速度慢,猪也显示出更快的胰岛素依赖性葡萄糖消除,而啮齿动物则显示出葡萄糖效应的差异。所得到的缩放 IGI 模型被证明可以准确预测外部临床前 IVGTT 数据,并且可能有助于将临床前研究转化为临床实践。